Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
International Journal of Radiation Oncology, Biology, Physics|July 13, 2010
Adherence to vaginal dilation following high dose rate brachytherapy for endometrial cancerLois C Friedman, Rita Abdallah, Mark Schluchter, et al.
The Annals of Otology, Rhinology, and Laryngology|October 7, 2008
Dexmedetomidine sedation for laryngeal framework surgeryRyan J Jense, Karen Souter, Jo Davies, et al.
Chest|November 29, 2012
Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 studyNicola Fazio, Dan Granberg, Ashley Grossman, et al.
Expert Review of Hematology|September 9, 2017
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agentPaul Richardson, Anuja Roy, Suddhasatta Acharyya, et al.
British Journal of Haematology|May 19, 2018
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trialPaul G Richardson, Robert L Schlossman, Anuja N Roy, et al.
The Oncologist|December 25, 2012
Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 studyDaniel Castellano, Emilio Bajetta, Ashok Panneerselvam, et al.
Future Oncology (London, England)|September 18, 2015
REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysisSergio Bracarda, Sylvie Rottey, Amit Bahl, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2012
Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 studyStéphane Oudard, Rokhaya Thiam, Laure S Fournier, et al.
Plos One|March 20, 2012
Topical application of activity-based probes for visualization of brain tumor tissueJennifer L Cutter, Nathan T Cohen, Jing Wang, et al.
Pancreas|December 6, 2014
Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trialCatherine Lombard-Bohas, James C Yao, Timothy Hobday, et al.
Pageof 3